rmhTNF-α Combined with Cisplatin Inhibits Proliferation of A549 Cell Line In Vitro
Le-min Xia1, *, Yi-yang Zhou2
1Department of Internal Medicine, 2Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Traditional Chinese Medicine University, Shanghai 200071, China
Le-min Xia, Yi-yang Zhou. rmhTNF-α Combined with Cisplatin Inhibits Proliferation of A549 Cell Line In Vitro[J].Chinese Medical Sciences Journal, 2014, 29(3): 185-187.
L, Guo J, Wang J, et al. Ad-KDRscFv: sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues. Int Immunopharmacol 2012; 13: 37- 45.
2.
SP. Cancer cell culture: Methods and protocols. Edinburgh: Humana Press Inc; 2004. p. 267-73.
3.
YY, Zhou NX, Huo JR. Pharmacodynamics and mechanism of rmhTNF in treating human gastric carcinoma. Gastroenterology 2010; 15: 261-6.
4.
L, Zhou QH, Gou HF, et al. Clinical effect and survival condition of non-small cell lung carcinoma treated by rmhTNF and combined chemotherapy. West China Med J 2008; 23: 521-2.
5.
M, Qin X, Xue X, et al. Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity. Anticancer Drugs 2010; 21: 243-51.
6.
NJ, Zhou SB, Diaz LA, et al. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011; 2: 739-51.
7.
GG, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol 2012; 92: 233-44.
8.
CL, Niu JZ, Li M, et al. Tumor vasculature-targeted recombinant mutated human TNF-α enhanced the antitumor activity of doxorubicin by increasing tumorvessel permeability in mouse xenograft models. PLoS One 2014; 9: e87036.